search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Selective laser trabeculoplasty (SLT) as replacement therapy in glaucoma patients


- candidate number22901
- NTR NumberNTR5417
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-sep-2015
- Secondary IDs4313 MEC
- Public TitleSelective laser trabeculoplasty (SLT) as replacement therapy in glaucoma patients
- Scientific TitleSelective laser trabeculoplasty as replacement therapy in glaucoma patients
- ACRONYMSLT
- hypothesis1. does pseudophakia influence intra ocular pressure (IOP) lowering effect of SLT?
2. the effect of SLT relies on an inflammatory reaction. Anti-inflammatory therapy is often used immediately following SLT, does this influence the IOP lowering effect or the side effects after SLT?
3. anti-glaucoma eye drops have a lot of side effects. Does SLT improve quality of life by reducing number of eye medications?
4. is there a significant difference in IOP lowering effect of SLT in low, normal or high tension glaucoma?
- Healt Condition(s) or Problem(s) studiedGlaucoma, Laser treatment
- Inclusion criteriapatients with ocular hypertension or chronic open angle glaucoma controlled by medical therapy. Patients had to be prepared to sign an informed consent document.
- Exclusion criteriaother types of glaucoma than open angle glaucoma, previous trabeculectomy or selective laser trabeculoplasty. Corneal disease that inhibit good visualization of the trabecular meshwork and patients taking systemic steroids are excluded
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2014
- planned closingdate1-sep-2016
- Target number of participants145
- Interventions1,Randomization decides whether patients receive SLT or continue on drops.
2,In those to receive SLT, randomization decides whether indomethacin or dexamethasone drops are given after SLT.
3,SLT is applied in both eyes, randomization decides in which eye the anti-inflammatory therapy (indomethacin or dexamethasone) is given, we start SLT always at the right eye.
4, SLT is performed, right eye first, the week after that, the other eye is treated. Eye that does not receive anti-inflammatory therapy is control eye.
- Primary outcome1, IOP lowering effect of SLT
- Secondary outcome1, inflammatory parameters after SLT ( redness, pain, cells in anterior chamber, IOP spike)
2, quality of life parameters
- Timepointsstart, 1 hour, 1 week, 1, 3, 6 and 12 months after SLT
- Trial web sitenone
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIES Myrjam de Keyser
- CONTACT for SCIENTIFIC QUERIES Myrjam de Keyser
- Sponsor/Initiator dr. M. De Keyser
- Funding
(Source(s) of Monetary or Material Support)
Universitair Ziekenhuis van Antwerpen
- Publications
- Brief summaryGlaucoma is a very common chronic disease. Selective laser trabeculoplasty (SLT) has the advantage of eliminating the side effects that are very common after using anti-glaucoma eye drops. We aim to investigate several aspects of SLT
- Main changes (audit trail)
- RECORD23-sep-2015 - 29-okt-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl